News regarding Cancer Crosslinks

Illustration photo: Shutterstock

Targovax Releases Positive Clinical Results

Targovax has received very positive results regarding the survival rate of patients with pancreatic cancer.

Immune-oncology aims to help the body’s own immune system fight cancer and the ambition is to address the unmet need for long-term survival for patients with advanced cancers.

13 of 13
The company specializes in immune-oncology and is a member of Oslo Cancer Cluster. It recently released information revealing that 13 of 13 test subjects where alive after one year of treatment in a stage two clinical trial study. In addition, an active immune response–meaning the immune system was triggered to attack the cancer–was observed in as much as 11 of 13 patients.

No allergic reactions
These results came after the number of test subjects were reduced from 19 to 13 to see if allergic reactions stalled with reduced dosages of the TG01; Targovax’s lead RAS immunotherapy product. And luckily, no serious allergic reactions were observed,

Magnus  Jäderberg MD, Chief Medical Officer of Targovax, said:

– We are delighted that we maintain a strong immune response and one-year survival rate with the reduced dosing  regimen, essentially  equivalent  to  and  consistent with the previously  reported data  from the  main cohort.

These new results are so positive that stock market analysts DnB Markeds predict a serious stock market rise for Targovax.

 

About Targovax

Arming the patient’s immune system to fight cancer

Targovax is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.

In July, 2016 the Company listed its shares on Oslo Axess.

Read more

 

Podcast on cancer research and development

Oslo Cancer Cluster member Radium Hospital Research Foundation, Radforsk, has launched their own podcast. The podcast is named Radium, and is about cancer research and development of new cancer treatments, as well as updates on Radforsk´s portfolio companies.

Radium has so far made nine episodes, and the ambition of Jónas Einarsson, CEO Radforsk and Elisabeth Kirkeng Andersen, communication manager in Radforsk, is to make one new episode a week. The podcasts are in Norwegian, if they do not interview people from abroad, as they did in the Cancer Crosslinks special.

Einarsson and Andersen is usually joined by guests in the studio, and so far they have had guests from Oslo Cancer Cluster members; PCI Biotech, Ultimovacs, Targovax, Vaccibody, Oncoinvent, as well as Roy Larsen and Øyvind Bruland, talking about Algeta, Nordic Nanovector and Oncoinvent.

Upcoming epiosodes will include guests such as Professor Håvard Danielsen from Institute for Cancer Genetics and Informatics, Anne Lise Ryel, General Secretary in the Norwegian Cancer Society and CEO, Kjetil Hestdal in Photocure.

Here you may find all podcast episodes launched so far.

Cancer Crosslinks 2017 will be streamed

Cancer Crosslinks 2017 on January 26th features a really interesting program with presentations from international and Norwegian thought leaders within cancer research.

For those of you that may not be present at the conference in the Oslo Cancer Cluster Innovation Park, you may watch the presentations as we will live stream from 9:15 – 16:15.

Close to 250 participants from all over Norway have signed up for this years Cancer Crosslinks. The program for the 9. th Cancer Crosslinks is divided in three parts; recent findings regarding cancer & inflammation, personalised cancer medicine within hematological cancers and the emerging field of real-world evidence.

Cancer Crosslinks is hosted by Oslo Cancer Cluster and sponsored by BMS and AbbVie.

PERMIDES project going forward with project manager hired

Oslo Cancer Cluster and NCE Smart Energy Markets together with four European clusters in medicine and IT managed to land a prestigious Horizon 2020 EU project this spring. The official kick-off for the project is September 7th to 8th in Karlsrue and project manager Gupta Udatha is hired to work in both Oslo and Halden to implement the project from Norwegian side.

 

Project manager Gupta Udatha He works at both the Norwegian Centres of Expertise located in Eastern Norway, i.e. Oslo Cancer Cluster and Smart Innovation Østfold. The PERMIDES project aims at establishing fruitful collaborations between the bio-pharmaceutical and IT sectors in the European region to advance the field of personalised medicine through the development of novel digital solutions with cancer as the model disease.

– Gupta has an amazing background from bioinformatics and big data analytics of biopharmaceutical data. We are confident he is going to drive this project forward in a satisfactory way, says Ketil Widerberg, CEO Oslo Cancer Cluster and Dieter Hirdes, F & I Coordinator Smart Innovation Østfold company as a leader NCE Smart Cluster in a joint comment.

The PERMIDES project will start 1 September and with a kick-off meeting in Karlsruhe 7th to 8th September.

 

 

View presentations and videos from Cancer Crosslinks

Cancer Crosslinks 2016 featured cutting-edge presentations from leading American and Norwegian clinicians and researchers within the field of cancer immunotherapy. You may look at their presentations again or for the first time via following the links below.  You may also watch videos of some of the presentations.

 

Picture above: The three Cancer Crosslinks 2016 keynote speakers.  From left: Professor Renier Brentjens, Dr. Stefanie Spranger and Professor Gordon Freeman.
Photo: U-Casters.

 

Videos:

International keynote presentations:

National presentations:

Presentations are published by courtesy of the lecturers.

Cancer Crosslinks 2016 will be streamed

Cancer Crosslinks 2016 features a really interesting program. For those of you that may not take part of the actual conference in the Oslo Cancer Cluster Innovation Park, you may watch the whole program at your computer as we will live stream from 9:00 – 16:30.

Over 240 people from all over Norway have signed up for this years Cancer Crosslinks. The program focuses on immuno-oncology and features strong international thought leaders as presenters. Cancer Crosslinks is hosted by Oslo Cancer Cluster and sponsored by BMS and Janssen.

 

 

 

Cancer Crosslinks 2016 features thought leaders in immuno-oncology

Cancer Crosslinks 2016 on January 14 offers you an exciting program with international keynote speakers who made and make major contributions to advance immunotherapies against cancer. Already more than 120 delegates have signed up, but we have room for many more in the Kaare Norum Auditorium at Oslo Cancer Cluster Innovation Park. The conference is sponsored by BMS and Janssen.

 

 

The main theme for Cancer Crosslinks 2016 is: «The transversal impact of new treatments in Oncology and Hematology: tumor microenvironment, novel concepts, combinations and study design».

 

Some program highlights:

  • Professor Gordon Freeman, Dana-Farber Cancer Institute and Harvard Medical School, is one of the key persons behind today’s PD-1/ PD-L1 inhibitors. He will share his perspectives on PD-1 cancer immunotherapy. His talk will be complemented by case studies from Norway illustrating the broad impact of immune checkpoint inhibitors for a variety of cancers
  • Professor  Renier Brentjens, Memorial Sloan-Kettering Cancer Center, will shift the focus to hematological cancers and discuss the advancement of recombinant T-cell technologies including CAR-T-cell approaches for different indications. Norwegian experts will complement his talk with updates on novel immuno-oncology approaches being developed at UiO and OUS
  • Stefani Spranger from Professor Tom Gajewski’s lab, University of Chicago will provide the latest insights into the role of T-cell inflammed versus non-inflammed tumor microenvironment for immunotherapy
  • Last, but not least: a Norwegian patient will share his perspectives on the importance of novel cancer therapies

 

Travel expences
Participants working at hospitals and/or academic reserach centres whom have no sources for funding the participation will get flight or train ticket covered. How ever we do not cover local transportation to / from the airport. Flight or train tickets may be ordered by connecting to travel agency Berg-Hansen on e-mail:  bestilling@berg-hansen.no or phone  08050 between 08.00-17.00. The reference code is «OCC».

View videos from Cancer Crosslinks 2015

At this years Cancer Crosslinks we made short video interviews with presenters Professor Paul Baas, Professor Nicholas Navin, Professor Bjørn Tore Gjertsen and Professor Kimmo Porkka on their research and views on cancer treatments in the future. You may watch them below.

We would like to thank the presenters for taking the time to share their knowledge and our sponsors Bristol-Myers Squibb and Roche for making it possible to produce these videos.

View presentations from Cancer Crosslinks

Cancer Crosslinks 2015 featured some very interesting, cutting-edge presentations from some of the leading cancer clinicians and researchers. Below we have published the presentations so you may watch them again or for the first time.

Presentations are published by courtesy of the lecturers.

 

 

 

 

 

Registration for Cancer Crosslinks 2015 is open

Cancer Crosslinks 2015 will be held January 15th at The Institute for Cancer Research at the Norwegian Radium Hospital. The program features several renowned international speakers as well as Norwegian experts. Main theme is “Novel insights into tumor heterogeneity and clonal evolution: how to design treatment and follow-up strategies”.

 

  • Program and registration form (close to the bottom of the page)
    Since the auditorium is usually fully booked for this event we limit the number of participants per company  to 2 people in the main auditorium. However,additional participants may follow the program from the seminar rooms and participate at lunch and networking parts. The meeting will also be streamed.

 

Exciting program bridging latest research and clinican implementation
In the first part of the program, international and Norwegian clinicians and researchers will discuss the clinical impact of approaches as single cell sequencing and liquid biopsies across different tumor types. We look forward to welcoming our keynote speakers Professor Nicholas Navin from MD Anderson and Professor Klaus Pantel from the University Hospital Hamburg–Eppendorf working at the international forefront in their fields

The second part deals with emerging treatment strategies integrating novel insights into tumor heterogeneity and building on both, molelularly targeted therapies and emerging cancer immunotherapies. You have the opportunity to hear recent insights from various tumor types and to discuss novel opportunities but also the challenges faced during the clinical implementation with our international and Norwegian speakers.

The third part is dedicated the patients perspective, where Anniken Golf Rokseth will share her story reminding all of us why we are putting our efforts into this area every day.

 

Welcome for the 7th time
Cancer Crosslinks 2015 is the seventh edition of this national meeting. This year’s event is hosted and developed in collaboration with BMS, Roche and the Norwegian Cancer Society. We thank our Program Committee with Bjørn Tore Gjertsen, Hans Petter Eikesdal, Christian Kersten and Ragnhild Lothe for their important contributions to the program development.

Presentations from Cancer Crosslinks 2014

Cancer Crosslinks 2014, January 23, was the 6th edition of this annual oncology conference bringing together hematologists, oncologists and the industry in Norway.

This years conference was developed and hosted in collaboration with partners BMS, Amgen and the Institute for Cancer Research, Oslo University Hospital. The feedback from the more than 220 participants was as always very positive, and we promise to come back with a even more exciting 7th edition of Cancer Crosslinks in January 2015.

Below you may find the main presentations featured at Cancer Crosslinks 2014, including the international keynote presentations from Professor Mario Sznol, Yale Cancer Centre and Professor Cornelis van de Velde, ECCO President. Here you may watch these presentations recorded at the Cancer Crosslinks conference.


Opening Keynotes:

“Opportunities, challenges and visions for cancer research and treatment”

Prof. Kjell Magne Tveit, Head of Department of Oncology, Oslo University Hospital

“Current trends in oncology drug development”
Prof. Gunnar Sæter, Head of the Institute for Cancer Research, Oslo University Hospital

Main session: New treatment modalities – need for a multidisciplinary approach

International Keynote:
“Cancer immunotherapies – novel treatment opportunities and their implications”
Prof. Mario Sznol, Yale Cancer Center, New Haven, CT, USA

International Keynote:

“Multidisciplinary collaboration for patient-centric oncology”
Prof. Cornelis van de Velde, Leiden University Medical Centre, Netherlands, ECCO President

“Optimizing treatment for each patient: MetAction as a Norwegian initiative”
Kjetil Boye MD, PhD; Oslo University Hospital as representative for the MetAction team
Find more info on Cancer Crosslinks 2014 here.